Osimertinib Mesylate
Sponsors
Bristol-Myers Squibb Services Unlimited Company, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Ono Pharmaceutical Co. Ltd, Jin Ying, Shanghai JMT-Bio Inc.
Conditions
Advance solid tumorsEGFR Mutation-Related TumorsLung Cancer, Nonsmall CellLung NeoplasmsNon Small Cell Lung CancerNon-Small Cell Lung CancerNon-small Cell Lung CancerRecurrent Non-Small Cell Lung Cancer
Phase 1
Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer
CompletedNCT06525246
Start: 2021-08-06End: 2025-06-23Updated: 2026-03-13
A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) combinations in Adult Participants with Advanced Solid Tumors
RecruitingCTIS2024-514947-27-00
Start: 2025-06-18Target: 108Updated: 2025-12-03
Phase 2
Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT)
NCT05085054
Start: 2022-06-01End: 2024-08-01Target: 30Updated: 2022-05-20
A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery
Not yet recruitingNCT06530719
Start: 2024-07-31End: 2028-05-31Target: 54Updated: 2024-07-31
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
RecruitingNCT07229729
Start: 2025-11-24End: 2029-10-31Target: 300Updated: 2025-12-01